5 January 2009: Dr. Roswitha Keller is hired as manager for sales & marketing Europe in NorDiag from January, 2009. Dr. Keller has extensive experience from the international diagnostic industry with leading positions in companies like Dynal Biotech, GenoVision and Qiagen. Dr. Keller will be part of NorDiag`s management team.

NorDiag has started to penetrate the European market with its CE IVD labeled instruments and reagents. NorDiag has already established a solid foothold and market share in Scandinavia and the strategy is to use the Scandinavian market as a reference market for further commercialization and geographic expansion.

Dr. Keller is expected to give a major contribution to this process, with her network, competence and industry knowledge.

Contact:             
CEO Mårten Wigstøl              
Phone: +47 91165775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing andmarketing automated solutions, instruments and tests, for diagnostic of infectious diseases and cancer. The company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis and MRSA. An application for respiratory pathogens is under development. NorDiag is also developing a test that shall contribute to early diagnosis of colorectal cancer. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The company has offices and laboratories in Bergen - Norway, Stockholm - Sweden and West Chester (PA) - USA. The group has 39 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here